Completed NA INTERVENTIONAL NCT00088192

Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD)

An Open Label, Non-Comparative Protocol for Use of Intravitreous Pegaptanib Sodium Injection Every 6 Weeks in Patients With Exudative Age-Related Macular Degeneration (AMD)

Sponsor: Eyetech Pharmaceuticals

Conditions Macular Degeneration

Interventions pegaptanib sodium

Updated 5 times since 2017 Last updated: Aug 29, 2005 Started: Jul 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Macular Degeneration, this trial is completed. The trial is conducted by Eyetech Pharmaceuticals and has accumulated 5 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Jul 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eyetech Pharmaceuticals
Pfizer

Data source: Eyetech Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Belleville, United States , Boston, United States , Bridgeport, United States , Burlington, United States , Columbia, United States , Concord, United States , Fort Myers, United States , Great Neck, United States , Hagerstown, United States , Hamden, United States and 9 more locations